See my options Quick answer Retatrutide (Eli Lilly) is a triple agonist (GLP-1, GIP, and glucagon) in Phase 3, with reported weight loss around 28% to 30% at higher doses, the strongest of the group so far
Perkovic V, Tuttle KR, Rossing P, et al
In people with type 2 diabetes, the combination showed a clinically relevant improvement in CGM profiles, with an impressive almost 90% [time in range] at 32 weeks, Mathieu said
The options may be chosen on the product page Peptide Research Overview Across scientific disciplines, peptide research supports advances in biochemistry and molecular biology
In addition, there are also inherent dangers with unnecessary injections and medications